ATE123030T1 - Piperidin-derivate, ihre herstellung und ihre verwendung. - Google Patents

Piperidin-derivate, ihre herstellung und ihre verwendung.

Info

Publication number
ATE123030T1
ATE123030T1 AT90102913T AT90102913T ATE123030T1 AT E123030 T1 ATE123030 T1 AT E123030T1 AT 90102913 T AT90102913 T AT 90102913T AT 90102913 T AT90102913 T AT 90102913T AT E123030 T1 ATE123030 T1 AT E123030T1
Authority
AT
Austria
Prior art keywords
preparation
piperidine derivatives
piperidine
derivatives
Prior art date
Application number
AT90102913T
Other languages
English (en)
Inventor
Per Sauerberg
Preben H Olesen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK82589A external-priority patent/DK82589A/da
Priority claimed from DK231589A external-priority patent/DK231589D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE123030T1 publication Critical patent/ATE123030T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT90102913T 1989-02-22 1990-02-14 Piperidin-derivate, ihre herstellung und ihre verwendung. ATE123030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK82589A DK82589A (da) 1989-02-22 1989-02-22 Piperidinforbindelser, deres fremstilling og anvendelse
DK231589A DK231589D0 (da) 1989-05-12 1989-05-12 Piperidinforbindelser og deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
ATE123030T1 true ATE123030T1 (de) 1995-06-15

Family

ID=26064725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90102913T ATE123030T1 (de) 1989-02-22 1990-02-14 Piperidin-derivate, ihre herstellung und ihre verwendung.

Country Status (22)

Country Link
US (5) US5043345A (de)
EP (2) EP0384288B1 (de)
JP (2) JP2921578B2 (de)
KR (1) KR0163763B1 (de)
CN (1) CN1028105C (de)
AR (1) AR247565A1 (de)
AT (1) ATE123030T1 (de)
AU (2) AU629302B2 (de)
CA (2) CA2010578C (de)
DE (1) DE69019550T2 (de)
DK (1) DK0384288T3 (de)
ES (1) ES2072323T3 (de)
FI (2) FI95704C (de)
GR (1) GR3017062T3 (de)
HU (2) HU221623B1 (de)
IE (1) IE69672B1 (de)
IL (2) IL93352A (de)
NO (2) NO179639C (de)
NZ (1) NZ232615A (de)
PH (1) PH26465A (de)
PT (2) PT93242A (de)
RU (1) RU2042676C1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372125A1 (de) * 1988-11-08 1990-06-13 Akzo N.V. Oxazol und Thiazol-Derivate
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
EP0459568A3 (en) * 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
USRE35822E (en) * 1990-08-21 1998-06-09 Novo Nordisk A/S Heterocyclic compounds
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
ATE164519T1 (de) * 1990-11-29 1998-04-15 Allergan Inc Verwendung von pyridine derivate zur behandlung der okulären hypertomie
EP0492903A1 (de) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituierte Pyrazine, Pyrimidine und Pyridazine zur Anwendung in der Behandlung von Glaukoma
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5641791A (en) * 1991-08-13 1997-06-24 Novo Nordisk A.S Heterocyclic compounds and their preparation and use
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5244906A (en) * 1992-01-23 1993-09-14 Dowelanco Insect control with substituted oxadiazole and thiadiazole compounds
CA2146019A1 (en) * 1992-10-23 1994-05-11 Howard B. Broughton Dopamine receptor subtype ligands
ATE196631T1 (de) * 1993-06-04 2000-10-15 Novo Nordisk As Xamonelin-tartrat
US5753683A (en) * 1993-08-19 1998-05-19 Novo Nordisk A/S Antipsychotic method
UA63876C2 (en) * 1993-08-19 2004-02-16 Novo Nordisk As Method for treating schizophrenia and schizophreniform disorders
US5545638A (en) * 1993-12-21 1996-08-13 Novo Nordisk A/S Method of treating gastrointestinal motility disorders
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5821370A (en) * 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5484794A (en) * 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
DE69516076T2 (de) * 1994-10-31 2000-09-14 Eli Lilly And Co., Indianapolis Tetrahydropyridin Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5612351A (en) * 1994-11-08 1997-03-18 Novo Nordisk A/S Method of treating urinary bladder dysfunctions
TW304167B (de) * 1995-01-30 1997-05-01 Lilly Co Eli
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
AU1128297A (en) * 1995-12-06 1997-06-27 Eli Lilly And Company Composition for treating pain
AU715645B2 (en) * 1995-12-07 2000-02-10 Eli Lilly And Company Method for treating pain
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
AU2991397A (en) * 1996-04-23 1997-11-12 Eli Lilly And Company Heterocyclic compounds
AU2738397A (en) * 1996-04-23 1997-11-12 Eli Lilly And Company Heterocyclic compounds
WO1997040045A1 (en) * 1996-04-24 1997-10-30 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
EP0821954A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
EP0821956A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung disruptiver Verhaltensstörungen
PT821955E (pt) * 1996-08-01 2002-07-31 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821957A3 (de) * 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821958A3 (de) * 1996-08-01 1998-07-08 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht
EP0821959A3 (de) * 1996-08-01 1998-09-16 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug
WO1998017214A1 (en) * 1996-10-23 1998-04-30 Eli Lilly And Company Method for treating dementia due to aids
JP2002500651A (ja) 1997-05-29 2002-01-08 ハー・ルンドベック・アクティーゼルスカブ 精神***病及び精神病の治療方法
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6376675B2 (en) * 1999-01-22 2002-04-23 The University Of Toledo Muscarinic receptor agonists
US6211204B1 (en) 1999-01-22 2001-04-03 University Of Toledo Muscarinic receptor agonists
US6096767A (en) * 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
WO2007025177A2 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
CN1821243B (zh) * 2005-08-30 2010-12-08 北京大学 取代的吡啶类m1受体激动剂、其制备方法及其用途
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1973904A2 (de) * 2005-12-27 2008-10-01 University Of Toledo Muscarinantagonisten und verfahren zu ihrer verwendung
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2296471A4 (de) 2008-05-15 2012-03-14 Univ Toledo Muskarinsäureagonisten als kognitive enhancer
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2020013374A (es) 2015-06-19 2022-05-06 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
EP3347011A4 (de) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation Muscarinkombination und deren verwendung zur bekämpfung von hypocholinergen störungen des zentralen nervensystems
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
US5017618A (en) * 1987-03-16 1991-05-21 University Of Florida Labile derivatives of ketone analogs of 3-substituted-1-alkylamino-2-propanols and their use as beta-adrenergic blockers
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK162892C (da) * 1988-07-04 1992-05-11 Novo Nordisk As 1,2,5,6-tetrahydropyridinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende disse
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists

Also Published As

Publication number Publication date
FI900886A0 (fi) 1990-02-22
FI95704C (fi) 1996-03-11
KR0163763B1 (ko) 1998-12-01
NO900830L (no) 1990-08-23
EP0384288A3 (de) 1991-04-10
NO900831D0 (no) 1990-02-21
FI95704B (fi) 1995-11-30
CN1028105C (zh) 1995-04-05
US5043345A (en) 1991-08-27
US5712297A (en) 1998-01-27
HU211705A9 (en) 1995-12-28
HUT58326A (en) 1992-02-28
US5284859A (en) 1994-02-08
JPH02255679A (ja) 1990-10-16
CA2010579A1 (en) 1990-08-22
NO179639B (no) 1996-08-12
PT93241B (pt) 1996-01-31
NO179639C (no) 1996-11-20
PT93241A (pt) 1990-08-31
NO900831L (no) 1990-08-23
PH26465A (en) 1992-07-27
AU4999790A (en) 1990-08-30
EP0384285A3 (de) 1991-04-24
GR3017062T3 (en) 1995-11-30
JPH02255680A (ja) 1990-10-16
US5041455A (en) 1991-08-20
NZ232615A (en) 1992-06-25
CA2010578A1 (en) 1990-08-22
AU4999690A (en) 1990-08-30
IL93423A0 (en) 1990-11-29
IL93352A0 (en) 1990-11-29
DE69019550D1 (de) 1995-06-29
DE69019550T2 (de) 1995-10-05
EP0384288A2 (de) 1990-08-29
RU2042676C1 (ru) 1995-08-27
CA2010578C (en) 2000-05-23
IE69672B1 (en) 1996-10-02
EP0384288B1 (de) 1995-05-24
DK0384288T3 (da) 1995-10-02
HU900884D0 (en) 1990-05-28
US5559138A (en) 1996-09-24
CN1045104A (zh) 1990-09-05
KR910015569A (ko) 1991-09-30
PT93242A (pt) 1990-08-31
ES2072323T3 (es) 1995-07-16
IL93352A (en) 1994-08-26
EP0384285A2 (de) 1990-08-29
NO900830D0 (no) 1990-02-21
AU629302B2 (en) 1992-10-01
AR247565A1 (es) 1995-01-31
HU221623B1 (hu) 2002-12-28
FI900887A0 (fi) 1990-02-22
IE900504L (en) 1990-08-22
JP2921578B2 (ja) 1999-07-19

Similar Documents

Publication Publication Date Title
DE69019550D1 (de) Piperidin-Derivate, ihre Herstellung und ihre Verwendung.
DE3885534D1 (de) Arylphosphorderivate, ihre Herstellung und Verwendung.
ATE89560T1 (de) Makrolid-derivate, ihre herstellung und ihre verwendung.
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE68910853D1 (de) Triazol-Derivate, ihre Herstellung und ihre Verwendung als Fungizide.
DE3777366D1 (de) 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
DE3788709D1 (de) Piperidin-Derivate, ihre Herstellung und Anwendung.
DE69028381D1 (de) PTC-Zusammensetzungen, ihre Herstellung und ihre Verwendung
ATA3589A (de) Neue isochinolinderivate, ihre herstellung und ihre verwendung
DE69027170D1 (de) Uracilderivate, ihre Herstellung und ihre Verwendung
DE3879024D1 (de) Pyridinium-derivate, ihre herstellung und verwendung.
DE59208576D1 (de) 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
ATE73805T1 (de) Makrolid-verbindungen, ihre herstellung und ihre verwendung.
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE3784602D1 (de) Inonos-derivate, ihre herstellung und verwendung.
DE3883297D1 (de) Phenolderivate, ihre herstellung und verwendung.
DE3863191D1 (de) Substituierte aminderivate, ihre herstellung und verwendung.
DE68908389D1 (de) Amidofluoroverbindungen, ihre herstellung und ihre verwendung.
DE68919259D1 (de) N-Phenylimide, ihre Herstellung und Verwendung.
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
DE59200365D1 (de) Cyclische Isolongifolanon-Ketale, ihre Herstellung und ihre Verwendung.
DE3879328D1 (de) Stannosilikate, ihre herstellung und verwendung.
DE3770299D1 (de) 1,2,4-triazinonderivate, ihre herstellung und verwendung.
DE69008085D1 (de) Oxetanocinderivate, ihre Salze und ihre Verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee